There were no IPOs this past week, but initial filings from a biotech and a Chinese issuer are keeping the IPO market moving. After another strong week, the IPO Index is now up about 35% from its March lows. As we pointed out in our ...read more
In early April, a short seller accused Chinese coffee chain Luckin (LK) of massively overstating revenues. A day later Chinese education provider TAL reported a non-material overstatement of revenues by an errant employee...read more
Luckin Coffee's (LK) alleged financial fraud and decline from an investor favorite to a penny stock is only the tip of the iceberg for the generally poor performance and Western investor skepticism of Chinese IPOs.
...read more
Another biotech IPO has beaten the market blues. Keros Therapeutics (KROS) finished the week up 35%, affirming that the biotech industry won’t be deterred by current market volatility. Oncology biotech Keros Therapeutics priced its...read more
US IPO Weekly Recap: 2 new filings keep the IPO market moving
There were no IPOs this past week, but initial filings from a biotech and a Chinese issuer are keeping the IPO market moving. After another strong week, the IPO Index is now up about 35% from its March lows. As we pointed out in our ...read more
A Longer View of IPO Fraud and Financial Restatements
In early April, a short seller accused Chinese coffee chain Luckin (LK) of massively overstating revenues. A day later Chinese education provider TAL reported a non-material overstatement of revenues by an errant employee...read more
Luckin Coffee’s financial scandal brews more trouble for Chinese IPOs
Luckin Coffee's (LK) alleged financial fraud and decline from an investor favorite to a penny stock is only the tip of the iceberg for the generally poor performance and Western investor skepticism of Chinese IPOs. ...read more
US IPO Weekly Recap: Keros Therapeutics rises 35% as biotechs beat the IPO shutdown
Another biotech IPO has beaten the market blues. Keros Therapeutics (KROS) finished the week up 35%, affirming that the biotech industry won’t be deterred by current market volatility. Oncology biotech Keros Therapeutics priced its...read more